1. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288(3):335–44.
2. World Health Organization. Coronavirus disease (COVID-19). Technical guidance. 2020. https://www.who.int/fr/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Accessed 30 Nov 2020.
3. Haut Conseil de la Santé Publique. Avis relatif à la prise en charge des cas confirmés d’infection au virus SARS-CoV2. 5. 2020. https://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=771. Accessed 30 Nov 2020.
4. WHO R&D Blueprint. Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection. 2020. https://apps.who.int/iris/bitstream/handle/10665/330680/WHO-HEO-RDBlueprint%28nCoV%29-2020.1-eng.pdf?ua=1. Accessed 30 Nov 2020.
5. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–34.